B
Birju Mehta
Researcher at Center for Cell and Gene Therapy
Publications - 19
Citations - 909
Birju Mehta is an academic researcher from Center for Cell and Gene Therapy. The author has contributed to research in topics: Medicine & Antigen. The author has an hindex of 6, co-authored 11 publications receiving 500 citations.
Papers
More filters
Journal ArticleDOI
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
Andras Heczey,Chrystal U. Louis,Barbara Savoldo,Olga Dakhova,April G. Durett,Bambi Grilley,Hao Liu,Mengfeng F. Wu,Zhuyong Mei,Adrian P. Gee,Birju Mehta,Huimin Zhang,Nadia Mahmood,Haruko Tashiro,Helen E. Heslop,Gianpietro Dotti,Cliona M. Rooney,Malcolm K. Brenner +17 more
TL;DR: CARTs are safe, and Cy/Flu can further increase their expansion, which may have contributed to the modest early antitumor responses; the effect of these cells merits further study.
Journal ArticleDOI
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Carlos A. Ramos,Carlos A. Ramos,Natalie S Grover,Anne W. Beaven,Premal Lulla,Premal Lulla,Meng Fen Wu,Meng Fen Wu,Anastasia Ivanova,Tao Wang,Tao Wang,Thomas C. Shea,Cliona M. Rooney,Cliona M. Rooney,Christopher Dittus,Steven I. Park,Adrian P. Gee,Adrian P. Gee,Paul Eldridge,Kathryn McKay,Birju Mehta,Catherine Cheng,Faith Brianne Buchanan,Bambi Grilley,Kaitlin Morrison,Malcolm K. Brenner,Malcolm K. Brenner,Jonathan S. Serody,Gianpietro Dotti,Helen E. Heslop,Helen E. Heslop,Barbara Savoldo +31 more
TL;DR: Heavily pretreated patients with relapsed or refractory HL who received fludarabine-based lymphodepletion followed by CD30.CAR-Ts had a high rate of durable responses with an excellent safety profile, highlighting the feasibility of extending CAR-T cell therapies beyond canonical B-cell malignancies.
Journal ArticleDOI
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Carlos A. Ramos,Carlos A. Ramos,Rayne H. Rouce,Catherine Robertson,Amy Reyna,Neeharika Narala,Gayatri Vyas,Birju Mehta,Huimin Zhang,Olga Dakhova,George Carrum,George Carrum,Rammurti T. Kamble,Rammurti T. Kamble,Adrian P. Gee,Zhuyong Mei,Meng Fen Wu,Hao Liu,Bambi Grilley,Bambi Grilley,Cliona M. Rooney,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner,Barbara Savoldo,Barbara Savoldo,Gianpietro Dotti,Gianpietro Dotti +27 more
TL;DR: 3G CD19.CARTs combining 4-1BB with CD28 produce superior CART expansion and may be of particular value when treating low disease burden in patients whose normal B cells are depleted by prior therapy.
Journal ArticleDOI
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
Meenakshi Hegde,Meenakshi Hegde,Sujith K. Joseph,Sujith K. Joseph,Farzana Pashankar,Christopher DeRenzo,Christopher DeRenzo,Khaled Sanber,Shoba A. Navai,Shoba A. Navai,Tiara T. Byrd,Tiara T. Byrd,John Hicks,Mina L. Xu,Claudia Gerken,Claudia Gerken,Mamta Kalra,Mamta Kalra,Catherine Robertson,Huimin Zhang,Ankita Shree,Ankita Shree,Birju Mehta,Olga Dakhova,Vita S. Salsman,Vita S. Salsman,Bambi Grilley,Bambi Grilley,Adrian P. Gee,Adrian P. Gee,Gianpietro Dotti,Helen E. Heslop,Malcolm K. Brenner,Winfried S. Wels,Stephen Gottschalk,Nabil Ahmed +35 more
TL;DR: A child with metastatic rhabdomyosarcoma who has durable response to HER2-specific CAR T cells and shows endogenous immune reactivity is described, which is 20 months off T-cell infusions with no detectable disease.
Journal ArticleDOI
Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells
Miyuki Tanaka,Haruko Tashiro,Bilal Omer,Bilal Omer,Natasha Lapteva,Jun Ando,Minhtran C. Ngo,Minhtran C. Ngo,Birju Mehta,Gianpietro Dotti,Gianpietro Dotti,Paul R. Kinchington,Ann M. Leen,Ann M. Leen,Claudia Rossig,Cliona M. Rooney +15 more
TL;DR: Vaccination via the TCR may provide a means to reactivate CAR-T cells rendered dysfunctional by the tumor microenvironment (NCT01953900), and was validated by the observation that T cells specific for these antigens expanded in vivo after VZV vaccination.